BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

157 related articles for article (PubMed ID: 30299248)

  • 1. Serum calprotectin as a marker of ultrasound-detected synovitis in early psoriatic and rheumatoid arthritis: results from a cross-sectional retrospective study.
    Sakellariou G; Lombardi G; Vitolo B; Gomarasca M; Faraldi M; Caporali R; Banfi G; Montecucco C
    Clin Exp Rheumatol; 2019; 37(3):429-436. PubMed ID: 30299248
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Calprotectin and TNF trough serum levels identify power Doppler ultrasound synovitis in rheumatoid arthritis and psoriatic arthritis patients in remission or with low disease activity.
    Inciarte-Mundo J; Ramirez J; Hernández MV; Ruiz-Esquide V; Cuervo A; Cabrera-Villalba SR; Pascal M; Yagüe J; Cañete JD; Sanmarti R
    Arthritis Res Ther; 2016 Jul; 18(1):160. PubMed ID: 27391315
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Calprotectin strongly and independently predicts relapse in rheumatoid arthritis and polyarticular psoriatic arthritis patients treated with tumor necrosis factor inhibitors: a 1-year prospective cohort study.
    Inciarte-Mundo J; Ramirez J; Hernández MV; Ruiz-Esquide V; Cuervo A; Cabrera-Villalba SR; Pascal M; Yagüe J; Cañete JD; Sanmarti R
    Arthritis Res Ther; 2018 Dec; 20(1):275. PubMed ID: 30545393
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Serum calprotectin (S100A8/9): an independent predictor of ultrasound synovitis in patients with rheumatoid arthritis.
    Hurnakova J; Zavada J; Hanova P; Hulejova H; Klein M; Mann H; Sleglova O; Olejarova M; Forejtova S; Ruzickova O; Komarc M; Vencovsky J; Pavelka K; Senolt L
    Arthritis Res Ther; 2015 Sep; 17(1):252. PubMed ID: 26373925
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Calprotectin (S100A8/A9) has the strongest association with ultrasound-detected synovitis and predicts response to biologic treatment: results from a longitudinal study of patients with established rheumatoid arthritis.
    Nordal HH; Brokstad KA; Solheim M; Halse AK; Kvien TK; Hammer HB
    Arthritis Res Ther; 2017 Jan; 19(1):3. PubMed ID: 28081709
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Relationship between serum calprotectin (S100A8/9) and clinical, laboratory and ultrasound parameters of disease activity in rheumatoid arthritis: A large cohort study.
    Hurnakova J; Hulejova H; Zavada J; Hanova P; Komarc M; Mann H; Klein M; Sleglova O; Olejarova M; Forejtova S; Ruzickova O; Vencovsky J; Pavelka K; Senolt L
    PLoS One; 2017; 12(8):e0183420. PubMed ID: 28832684
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Serum Calprotectin Versus Acute-Phase Reactants in the Discrimination of Inflammatory Disease Activity in Rheumatoid Arthritis Patients Receiving Tumor Necrosis Factor Inhibitors.
    Inciarte-Mundo J; Victoria Hernández M; Ruiz-Esquide V; Raquel Cabrera-Villalba S; Ramirez J; Cuervo A; Pascal M; Yagüe J; Cañete JD; Sanmarti R
    Arthritis Care Res (Hoboken); 2016 Jul; 68(7):899-906. PubMed ID: 26841119
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The soluble biomarker calprotectin (an S100 protein) is associated to ultrasonographic synovitis scores and is sensitive to change in patients with rheumatoid arthritis treated with adalimumab.
    Hammer HB; Fagerhol MK; Wien TN; Kvien TK
    Arthritis Res Ther; 2011; 13(5):R178. PubMed ID: 22029973
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Differing local and systemic inflammatory burden in polyarticular psoriatic arthritis and rheumatoid arthritis patients on anti-TNF treatment in clinical remission.
    Ramírez J; Inciarte-Mundo J; Cuervo A; Ruiz-Esquide V; Hernández MV; Sanmartí R; Cañete JD
    Clin Exp Rheumatol; 2017; 35(1):74-79. PubMed ID: 27749227
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Calprotectin as a marker of inflammation in patients with early rheumatoid arthritis.
    Jonsson MK; Sundlisæter NP; Nordal HH; Hammer HB; Aga AB; Olsen IC; Brokstad KA; van der Heijde D; Kvien TK; Fevang BS; Lillegraven S; Haavardsholm EA
    Ann Rheum Dis; 2017 Dec; 76(12):2031-2037. PubMed ID: 28814431
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Calprotectin (S100A8/A9) and S100A12 are associated with measures of disease activity in a longitudinal study of patients with rheumatoid arthritis treated with infliximab.
    Nordal HH; Brun JG; Hordvik M; Eidsheim M; Jonsson R; Halse AK
    Scand J Rheumatol; 2016 Jul; 45(4):274-81. PubMed ID: 26767827
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Calprotectin (S100A8/A9) should preferably be measured in EDTA-plasma; results from a longitudinal study of patients with rheumatoid arthritis.
    Nordal HH; Fagerhol MK; Halse AK; Hammer HB
    Scand J Clin Lab Invest; 2018; 78(1-2):102-108. PubMed ID: 29278951
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Calprotectin more accurately discriminates the disease status of rheumatoid arthritis patients receiving tocilizumab than acute phase reactants.
    Inciarte-Mundo J; Ruiz-Esquide V; Hernández MV; Cañete JD; Cabrera-Villalba SR; Ramirez J; Yagüe J; Sanmarti R
    Rheumatology (Oxford); 2015 Dec; 54(12):2239-43. PubMed ID: 26242859
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Serum Calprotectin Discriminates Subclinical Disease Activity from Ultrasound-Defined Remission in Patients with Rheumatoid Arthritis in Clinical Remission.
    Hurnakova J; Hulejova H; Zavada J; Komarc M; Hanova P; Klein M; Mann H; Sleglova O; Olejarova M; Forejtova S; Ruzickova O; Vencovsky J; Pavelka K; Senolt L
    PLoS One; 2016; 11(11):e0165498. PubMed ID: 27832086
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Serum levels of CXCL13 are associated with ultrasonographic synovitis and predict power Doppler persistence in early rheumatoid arthritis treated with non-biological disease-modifying anti-rheumatic drugs.
    Bugatti S; Manzo A; Benaglio F; Klersy C; Vitolo B; Todoerti M; Sakellariou G; Montecucco C; Caporali R
    Arthritis Res Ther; 2012 Feb; 14(1):R34. PubMed ID: 22336440
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A Proposed Serum Calprotectin IgG Cut-Off Level for Diagnosing Inflammatory Arthritis.
    Grossi V; Infantino M; Manfredi M; Meacci F; Bellio E; Bellio V; Gobbi FL; Ugolini S; Catani S; Sarzi-Puttini P; Atzeni F; Benucci M
    Curr Rheumatol Rev; 2017; 13(2):93-97. PubMed ID: 27363504
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Calprotectin in rheumatoid arthritis : association with disease activity in a cross-sectional and a longitudinal cohort.
    García-Arias M; Pascual-Salcedo D; Ramiro S; Ueberschlag ME; Jermann TM; Cara C; Martín-Mola E; Balsa A
    Mol Diagn Ther; 2013 Feb; 17(1):49-56. PubMed ID: 23329363
    [TBL] [Abstract][Full Text] [Related]  

  • 18. S100 proteins calprotectin and S100A12 are related to radiographic changes rather than disease activity in psoriatic arthritis with low disease activity.
    Madland TM; Larsen A; Brun JG
    J Rheumatol; 2007 Oct; 34(10):2089-92. PubMed ID: 17787039
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Calprotectin (a major leucocyte protein) is strongly and independently correlated with joint inflammation and damage in rheumatoid arthritis.
    Hammer HB; Odegard S; Fagerhol MK; Landewé R; van der Heijde D; Uhlig T; Mowinckel P; Kvien TK
    Ann Rheum Dis; 2007 Aug; 66(8):1093-7. PubMed ID: 17234650
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clinical and sonographic biomarkers of structural damage progression in RA patients in clinical remission: A prospective study with 12 months follow-up.
    Ramírez J; Narváez JA; Ruiz-Esquide V; Hernández-Gañán J; Cuervo A; Inciarte-Mundo J; Hernández MV; Sampayo-Cordero M; Pablos JL; Sanmartí R; Cañete JD
    Semin Arthritis Rheum; 2017 Dec; 47(3):303-309. PubMed ID: 28549731
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.